Modificare „Kiniksa Pharmaceuticals, Ltd”

Pagina dedicata companiei Kiniksa Pharmaceuticals, Ltd listata cu simbolul US.KNSA

==Descriere companie==
Kiniksa Pharmaceuticals, Ltd. (www.kiniksa.com) is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.KNSA" />

==Ultimele stiri despre Kiniksa Pharmaceuticals, Ltd (US.KNSA)==
<dynamicpagelist>
category=US.KNSA
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.KNSA]][[Categorie:Stiri despre companii]]